Posted by Michael Wonder on 28 Jun 2022
Curium announces the submission of its marketing authorisation application for [18F]-DCFPyL to the EMA
27 June 2022 - Submission follows the completion of Phase III PYTHON clinical trial of [18F]-DCFPyL for recurrent prostate cancer in Europe in May 2022.
Curium today announced the submission of its marketing authorisation application for [18F]-DCFPyL to the EMA.
